Clinical Significance of MiR-137 Expression in Patients with Gastric Cancer After Radical Gastrectomy

Abstract

The dysregulation of miR-137 plays vital roles in the oncogenesis and progression of various types of cancer, but its role in prognosis of gastric cancer patients remains unknown. This study was designed to investigate the expression and prognostic significance of miR-137 in gastric cancer patients after radical gastrectomy. Quantitative real-time PCR (qRT-PCR) was performed to evaluate the expression of miR-137 in human gastric cancer cell lines and tissues in patients with gastric adenocarcinoma. Results were assessed for association with clinical factors and overall survival by using Kaplan-Meier analysis. Prognostic values of miR-137 expression and clinical outcomes were evaluated by Cox regression analysis. The results exhibited that the expression level of miR-137 was decreased in human gastric cancer cell lines and tissues, and down-regulated expression of miR-137 was associated with tumor cell differentiation, N stage, and TNM stage. Decreased miR-137 expression in gastric cancer tissues was positively correlated with poor overall survival of gastric cancer patients. Further multivariate Cox regression analysis suggested that miR-137 expression was an independent prognostic indicator for gastric cancer except for TNM stage. Applying the prognostic value of miR-137 expression to TNM stage III group showed a better risk stratification for overall survival. In conclusion, the results reinforced the critical role for the down-regulated miR-137 expression in gastric cancer and suggested that miR-137 expression could be a prognostic indicator for this disease. In addition, these patients with TNM stage III gastric cancer and low miR-137 expression might need more aggressive postoperative treatment and closer follow-up.

Genome-wide analysis to identify a novel microRNA signature that predicts survival in patients with stomach adenocarcinoma

“…However, our current study indicated miR-137 dysregulation between STAD and adjacent normal tissue samples, with STAD tissue being down-regulated, a finding supported by previous gastric cancer studies 55, 59. Additionally, decreased miR-137 expression is correlated to a higher-grade and more advanced tumor phase 55, 60. Gu et al reported that in 154 gastric cancer patients, lower miR-137 expression levels are significantly correlated to poor clinical outcomes 60.…”

“…Additionally, decreased miR-137 expression is correlated to a higher-grade and more advanced tumor phase 55, 60. Gu et al reported that in 154 gastric cancer patients, lower miR-137 expression levels are significantly correlated to poor clinical outcomes 60. Contrarily, in our study which comprised 408 STAD patients, a higher miR-137 expression level was remarkably associated with poor OS.…”

Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis

“…Cut-off values of high or low miRs expression were mainly mean and median values. As for clinical endpoints, there were 46 studies [ 1 , 2 , 10 – 12 , 16 , 20 , 22 , 24 – 27 , 29 – 33 , 36 – 41 , 43 – 59 , 61 – 66 ] including overall survival (OS), 5 studies [ 67 – 71 ] including disease free survival (DFS) and another 9 studies [ 18 , 19 , 21 , 23 , 28 , 34 , 35 , 42 , 60 ] including both OS and DFS. We have identified a total of 59 miRs including 23 significantly up-regulated expression miRs (miR-214, miR-17, miR-20a, miR-200c, miR-107, miR-27a, miR-196b, miR-222, miR-106b, miR-500, miR-377, miR-25, miR-181a, miR-183, miR-1288, miR-106a-5p, miR-21, miR-30e, miR-142-3p, miR-1246, miR-508, miR-503, miR-942) and 36 significantly down-regulated expression miRs (miR-433, let-7g, miR-125a-5p, miR-760, miR-206, miR-26a, miR-200b, miR-185, miR-22, miR-217, miR-506, miR-133, miR-218, miR-137, miR-326, miR-486-5p, miR-29, miR-23b-3p, miR-194, miR-451, miR-34a, miR-106a, miR-143, miR-16, miR-139-3p, miR-361-5p, miR-365, miR-338-3p, miR-200c, miR-141, miR-150, miR-138, miR-134a, miR-195, miR-203, miR-375) correlated with poor prognosis in GIC patients (Table 1 , Table 2 ).…”

Aspirin inhibits the proliferation and migration of gastric cancer cells in p53-knockout mice

“…The average 5-year survival rate following surgery is ≤30%. Invasion and metastasis are the main causes of death in patients with gastric cancer (9). …”